All In Biotech

Drug Trial Radar · NCT00571727

Long-Term Treatment With rhIGF-1 in GHIS

A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)

Last checked: Nov 20, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

92

Actual

Start

May 20, 1991

Primary completion

Dec 15, 2011

Study completion Dec 15, 2011

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
Collaborators
University of Oklahoma
First posted
Dec 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).

Conditions

  • Growth Hormone Insensitivity Syndrome

Interventions

  • mecaserminDrug

    injections BID of rhIGF-1, mecasermin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Height Velocity Up to 12 YearsTime frame: Baseline (Pre-dose) and up to 12 years
  2. Number of Naive Participants With Height Velocity <5 cm/y at the End of 1 Year of Study TreatmentTime frame: Baseline (Pre-dose) and 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ipsen

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.